Press Releases
To stay up to date on the latest news, follow Simpson Interventions on LinkedIn.
Jun 12, 2024
Simpson Interventions Announces Appointment of Dr. Joseph Knight as CEO
Prior CEO and Founder, Dr. John Simpson, to Remain with Company as Chief Medical Officer and Continue his Role as Chairman of the Board of Directors Campbell, Calif. – June 12, 2024 - Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced the appointment of Dr. Joseph Knight to the role of Chief Executive Officer, effective May 1st, 2024. He replaces Simpson Interventions’ Founder and previous CEO, Dr. John B. Simpson, who will continue in his role as Chairman of the company’s Board of Directors, while additionally assuming the role of Chief Medical Officer. Dr. Simpson has been CEO since the founding of Simpson Interventions in 2019. Dr. Knight’s extensive academic credentials include a Ph.D. from the Swiss Federal Institute of Technology (ETH Zurich), an MBA in entrepreneurship and marketing form Duke University’s Fuqua School of Business, a Bachelor and Masters in engineering from the University of South Florida and as a Fellow in Stanford University’s Biodesign Innovation Program. Dr. Knight most recently served as President and CEO of InnAVasc Medical until the company was acquired by W. L. Gore & Associates. Additionally, Dr. Knight has been part of the intellectual property development, business, and strategic planning for multiple early-stage ventures – including iRhythm Technologies, Lacuna Medial, Higgs Boson Health and Medici Medical Technologies. Dr. Knight also spent five years at Medtronic in various marketing, business development, and strategy roles. “I’m thrilled to take the leadership mantle from Dr. Simpson, who has been a luminary in the field of cardiovascular medicine for generations,” said Dr. Knight. “Not only has Dr. Simpson grown Simpson Interventions into a company at the forefront of breakthroughs in interventional cardiology (IC), but he’s also had the foresight to tackle the complex problems that have plagued the interventional cardiology community for decades. I’m honored to be able to follow in his footsteps and lead this great company forward.” “I’ve always believed my strength lies in taking a company from the ‘device drawing on a napkin’ phase to the ‘First In Human’ phase,” said Dr. John B. Simpson, Ph.D., M.D., founder and previous CEO of Simpson Interventions, Inc. “Now that we have reached this critical milestone, it is the perfect time to bring in a leader with the operational expertise to guide us through the next stages of growth. Dr. Knight is exceptionally well-suited for this role, and I am thrilled to support him as Chief Medical Officer while we continue to revolutionize interventional cardiology together. His story is profoundly inspiring, and I am confident he will lead Simpson Interventions to new heights.” For more information about Simpson Interventions and its innovative medical technologies, please visit www.simpsonint.com. About Simpson Interventions: Simpson Interventions is a leading medical technology company committed to addressing unmet clinical needs in cardiovascular diseases through technological innovations in visual-guidance, enhanced intelligence, and electromechanical automation for minimally invasive percutaneous intervention. For more information: www.simpsonint.com Media Contact: Steve Kelly Simpson Interventions Email: stevek@simpsonint.com
May 15, 2024
Simpson Interventions Accepted into FDA's TAP Pilot Program for Breakthrough Device, Acolyte™ Catheter System
Campbell, Calif. - May 15, 2024 - Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced its acceptance into the Total Product Life Cycle Advisory Program Pilot (TAP Pilot) by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). Only devices granted Breakthrough Device designation by the FDA may apply to enroll in the TAP Pilot Program. This voluntary program is designed to help ensure U.S. patients have access to high-quality, safe, effective, and innovative medical devices by promoting early, frequent, and strategic communications between the FDA and medical device sponsors. Simpson Intervention’s Acolyte Catheter System was recently designated as a Breakthrough Device on March 4, 2024. The Acolyte Catheter System is a cutting-edge technology intended to facilitate the placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions with persistent symptoms following medical therapy. By providing real-time visualization of coronary chronic total occlusions, the Acolyte Catheter System allows for precise guidewire placement and subsequent revascularization, improving patient outcomes and enhancing the standard of care. "Simpson Interventions is honored to be accepted into the FDA's TAP Pilot Program for our Acolyte Catheter System," said Dr. John B. Simpson, PhD, MD, founder and CEO of Simpson Interventions. "This acknowledgment underscores the innovative nature of the device and its potential to address an unmet medical need in the field of interventional cardiology. We look forward to working closely with the FDA to advance the development and commercialization of this breakthrough technology." Simpson Interventions remains steadfast in its mission to bring transformative medical technologies to market, and the acceptance into the TAP Pilot Program marks a significant milestone in this journey. For more information about Simpson Interventions and its innovative medical technologies, please visit www.simpsonint.com. About Simpson Interventions: Simpson Interventions is a leading medical technology company committed to addressing unmet clinical needs in cardiovascular diseases through technological innovations in visual-guidance, enhanced intelligence, and electromechanical automation for minimally invasive percutaneous intervention. For more information: www.simpsonint.com Media Contact: Steve Kelly Simpson Interventions Email: stevek@simpsonint.com
Apr 11, 2024
Simpson Interventions Receives FDA Breakthrough Device Designation for Acolyte™ Image Guided Crossing and Re-Entry Catheter System
● Designation expedites the review of medical technologies that can improve the lives of patients with life-threatening or debilitating diseases or conditions ● The Acolyte System is intended to provide interventional cardiologists with a more reliable and predictable tool to facilitate revascularization of chronic total occlusion (CTO) ● Sixteen to twenty percent of patients with coronary artery disease have CTOs Campbell, Calif. – April 11, 2024 - Simpson Interventions, Inc., a pioneering medical technology company specializing in cardiovascular interventional devices, today announced that its groundbreaking Acolyte Image Guided Crossing and Re-Entry Catheter System has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). The Acolyte Image Guided Crossing and Re-Entry Catheter System is designed to facilitate the placement and positioning of guidewires and catheters within the coronary vasculature for the treatment of patients with coronary chronic total occlusions (CTOs) who continue to experience symptoms following medical therapy. This breakthrough device is poised to significantly change the approach to treating coronary CTOs by providing real-time optical coherence tomography (OCT) visualization, enabling precise guidewire placement within the target vessel's true lumen and subsequent revascularization. According to the Journal of the American College of Cardiology: Cardiovascular Interventions, sixteen to twenty percent of patients with coronary artery disease have CTOs , which occur when a coronary artery is completely blocked by plaque buildup, posing significant challenges for interventional cardiologists who struggle to traverse these lesions with current standard of care options. If a physician fails to cross a CTO, minimally invasive revascularization options such as angioplasty and stent placement cannot be performed. Hence, in the US, many CTO patients are instead sent for bypass surgery. The Acolyte Image Guided Crossing and Re-Entry Catheter System aims to overcome these challenges by providing clinicians with this breakthrough device that has enhanced visualization and navigation capabilities, ultimately improving CTO crossing, procedural success rates, and patient outcomes. "We are thrilled to receive FDA's Breakthrough Device Designation for our Acolyte Image Guided Crossing and Re-Entry Catheter System," said Dr. John B. Simpson, PhD, MD, Founder and CEO of Simpson Interventions. "This designation recognizes the transformative potential of our technology in addressing a critical unmet need in the treatment of patients with coronary chronic total occlusions. We are committed to advancing the field of interventional cardiology and improving patient outcomes through innovation." The FDA's Breakthrough Device Designation is granted to medical devices that offer potential advantages over existing technologies for the treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. This designation expedites the development, assessment, and review process, enabling patients to gain access to innovative medical technologies more quickly. Simpson Interventions is committed to collaborating closely with the FDA and other stakeholders to advance the development and regulatory review of the Acolyte Image Guided Crossing and Re-Entry Catheter System. The company looks forward to bringing this revolutionary technology to clinicians, and patients in need. For more information about Simpson Interventions and its innovative medical technologies, please visit www.simpsonint.com. About Simpson Interventions: Simpson Interventions is a leading medical technology company committed to addressing unmet clinical needs in cardiovascular diseases through technological innovations in visual-guidance, enhanced intelligence, and electromechanical automation for minimally invasive percutaneous intervention. For more information: www.simpsonint.com Media Contact: Steve Kelly Simpson Interventions Email: stevek@simpsonint.com